Category: Publications

Safety and Pharmacokinetics of the Oral Prostaglandin F2alpha Receptor Antagonist, OBE022, in Patients With Threatened Spontaneous Preterm Labor

Posted on by Sylwia Scheel-Krüger

Andrew Humberstone, Jose Luis Bartha, Seppo Heinonen, Juha Räsänen, Aydin Tekay, Michel Brethous, Jean-Pierre Gotteland, Oliver Pohl, Ernest Loumaye

SRI Conference, 12-16 March 2019, Paris, France
Abstract S-001: page 299A

Abstracts. Reprod. Sci. 26, A62–A390 (2019). https://doi.org/10.1177/1933719119834079

Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs

Posted on by Sylwia Scheel-Krüger

Simon Coates, Oliver Pohl, Jean-Pierre Gotteland, Jörg Täubel, Ulrike Lorch

Article first published online: January 27, 2019

Coates S, Pohl O, Gotteland JP, Täubel J, Lorch U. Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. Ther Innov Regul Sci. 2020;54(1):184‐194. doi:10.1007/s43441-019-00044-y

A Placebo-Controlled, Randomized, Double-Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer

Posted on by Sylwia Scheel-Krüger

Visnova H., Tournaye H. J., Humberstone A., Terrill P., Macgregor L., Loumaye E.

ASRM 2018, 6-10 October 2018, Denver, CO

Fertility and Sterility September 2018 Volume 110, Issue 4, Supplement, Page e45, Abstract O101

OBE022, an oral and selective prostaglandin F2α receptor antagonist as an effective and safe modality for the treatment of preterm labor

Posted on by Sylwia Scheel-Krüger

Pohl O, Chollet A, Kim SH, Riaposova L, Spezia F, Gervais F, Guillaume P, Lluel P, Meen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP.

Journal of Pharmacology and Experimental Therapeutics August 2018, 366 (2) 349-364; doi:10.1124/jpet.118.247668

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women

Posted on by Sylwia Scheel-Krüger

Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U

Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U. Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women. Br J Clin Pharmacol. 2018;84(8):1839‐1855. doi:10.1111/bcp.13622

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments

Posted on by Sylwia Scheel-Krüger

Jörg Täubel, Ulrike Lorch, Simon Coates, Sara Fernandes, Paul Foley, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl

Täubel, J., Lorch, U., Coates, S., Fernandes, S., Foley, P., Ferber, G., Gotteland, J.‐P. and Pohl, O. (2018), Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments. Clinical Pharmacology in Drug Development, 7: 889-900. doi:10.1002/cpdd.447

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue